asia pacific drug delivery system Market

The Asia Pacific drug delivery systems market is expected to reach US$ 441,337.0 Mn in 2027 from US$ 212,012.7 in 2018. The growth rate of the market in the region is estimated to be 8.6% during the forecast period.

The growth of the market is majorly contributed by the rising prevalence of the chronic disease across the region which is resulting into the higher demand for drug delivery systems. In addition, the growing adoption for non-invasive drug delivery devices and growing patient compliance are likely to enhance the growth of the market for the drug delivery systems.

The traditional drug delivery techniques, like intramuscular, intravenous, oral and rectal drug administration are not suitable to certain patient populations. The non-invasive methods of drug delivery reduces dosing frequency and simplifies dosing schedules. Moreover, non-invasive drug delivery system can significantly reduce the cost of clinical use because of self-administration of the drugs by the patients. The manufacturing cost may also be less for non-invasive dosage forms as compared to injections in many cases. For instance, inhaled insulin appears to be a non-invasive, well-tolerated and liked modality of treatment of diabetes and ongoing partnership or collaborations in Asia Pacific region is propelling the market of non-invasive drug delivery devices in Asia Pacific.

In 2018, Japan drug delivery systems market holds the largest share of the Asia Pacific drug delivery systems market. The hospital pharmacies segment expected to dominate the Asia Pacific drug delivery systems market. Additionally, this segment is also anticipated to witness the fastest growth rate during the forecast period, 2019 to 2027. Similarly, in 2018 retail pharmacies segment is estimated to hold the largest share and is also expected to grow at the fastest growth rate during the forecast period.

Some of the major primary and secondary sources for drug delivery systems included in the report are, International Diabetes Federation Centers for Diabetes and Endocrinology World Economic Forum, United Nations Population Fund, Council for Scientific and Industrial Research and etc.